CardioExchange Archive

September 5th, 2013

Rosiglitazone Revisited

Richard G. Bach, MD and John Ryan, MD

Richard G. Bach discusses his study group’s observational analysis of data from the BARI 2D trial regarding outcomes associated with rosiglitazone.

---

June 19th, 2013

Top-Line Results: No Cardiovascular Benefits Found For Saxagliptin

Larry Husten, PHD

Top-line results of a large phase 4 study with saxagliptin (Onglyza, Bristol-Myers Squibb and AstraZeneca) demonstrate that the drug is safe but has no cardiovascular benefits. AstraZeneca and Bristol-Myers Squibb today announced the top-line results for the SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza®. The full results are scheduled to presented at the annual meeting of the European Society of Cardiology in Amsterdam on September 2 […]

---

June 10th, 2013

Selections from Richard Lehman’s Literature Review: June 10th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include controlling diabetes through surgery or medical management, the risk for diabetes among those taking statins, and aspirin vs. low-molecular-weight heparin for extended VTE prophlyaxis after total hip replacement.

---

May 20th, 2013

Selections from Richard Lehman’s Literature Review: May 20th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the safety and efficacy of sitagliptin for type 2 diabetes, use of glucocorticoids and the risk of VTE, and forced smoking abstinence.

---

April 22nd, 2013

Selections from Richard Lehman’s Literature Review: April 22nd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the prevalence of a healthy lifestyle among those with CV disease in high-, middle-, and low-income countries, nonemergency PCI at hospitals with or without on-site cardiac surgery, and coronary artery calcium score prediction of all-cause mortality and CV events in those with type-2 diabetes.

---

April 2nd, 2013

Intensive Glucose Control and ESRD – Strongest Evidence?

Kasia Lipska, MD, MHS

Kasia Lipska unpacks a report in Kidney International that claims to provide “the strongest evidence yet” of a protective effect of intensive glucose lowering against end-stage renal disease in type 2 diabetes.

---

March 29th, 2013

FDA Approves First SGLT2 Inhibitor for Diabetes

Larry Husten, PHD

The FDA said today that it had approved canaglifozin (Invokana, Johnson & Johnson), the first of a new class of diabetes drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Canaglifozin is indicated, in conjunction with diet and exercise, to improve glycemic control in adults with type 2 diabetes. The drug has been studied as monotherapy and in combination with […]

---

January 14th, 2013

Advisory Panel Recommends Approval of Diabetes Drug Canagliflozin

Christine Sadlowski, MS

An advisory committee to the FDA recommended approving canagliflozin, a new type of drug for type 2 diabetes, late last week, the New York Times reports. The once-daily oral drug is a selective sodium glucose co-transporter 2 inhibitor. It prevents reabsorption of glucose by the kidney, thereby increasing glucose excretion in the urine and reducing blood […]

---

December 27th, 2012

Selections from Richard Lehman’s Literature Review: December 27th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include an intensive lifestyle intervention and its association with type-2 diabetes remission, strategies for multivessel revascularization in patients with diabetes, and more.

---

December 10th, 2012

Selections from Richard Lehman’s Literature Review: December 10th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of warfarin and new oral anticoagulants for managing AF and VTE, two studies of a monoclonal antibody to PCSK9 in patients with hypercholesterolemia, and more.

---